web analytics

Presentation of data where FG001 demonstrates dose-depended effectiveness in lightening up glioblastoma in a preclinical model

FluoGuide A/S’s (“FluoGuide”, ticker FLUO) compound FG001 lights up the cancer and has in preclinically studies demonstrated potential to vastly improve the radicality of surgery in different types of cancer. Today data was presented at World Molecular Imaging Congress 2019 (WMIC) in Montreal, demonstrating dose-dependent FG001 effectiveness in lightening up glioblastoma in a preclinical model.
Despite several decades of effort in improving the standard therapy of Glioblastoma (GBM), an aggressive form of cancer in the brain, the average life expectancy after a GBM diagnosis is only 14

Source: Presentation of data where FG001 demonstrates dose-depended effectiveness in lightening up glioblastoma in a preclinical model

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.